Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Sunday, January 23, 2022

New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2022 Jan 18:S0007-4551(21)00686-X. doi: 10.1016/j.bulcan.2021.10.007. Online ahead of print.

NO ABSTRACT

PMID:35063182 | DOI:10.1016/j.bulcan.2021.10.007

View on the web

No comments:

Post a Comment